Company’s 36-month beta value is 1.64.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MBOT is 16.11M, and currently, short sellers hold a 1.10% ratio of that floaft. The average trading volume of MBOT on September 06, 2024 was 242.66K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MBOT) stock’s latest price update
The stock of Microbot Medical Inc (NASDAQ: MBOT) has increased by 6.14 when compared to last closing price of 0.83.Despite this, the company has seen a loss of -7.40% in its stock price over the last five trading days. zacks.com reported 2024-08-23 that Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY.
MBOT’s Market Performance
Microbot Medical Inc (MBOT) has seen a -7.40% fall in stock performance for the week, with a -8.46% decline in the past month and a -24.39% plunge in the past quarter. The volatility ratio for the week is 5.98%, and the volatility levels for the past 30 days are at 5.19% for MBOT. The simple moving average for the past 20 days is -9.22% for MBOT’s stock, with a -23.23% simple moving average for the past 200 days.
Analysts’ Opinion of MBOT
Many brokerage firms have already submitted their reports for MBOT stocks, with H.C. Wainwright repeating the rating for MBOT by listing it as a “Buy.” The predicted price for MBOT in the upcoming period, according to H.C. Wainwright is $26 based on the research report published on January 13, 2020 of the previous year 2020.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see MBOT reach a price target of $12, previously predicting the price at $10. The rating they have provided for MBOT stocks is “Buy” according to the report published on December 24th, 2019.
Ladenburg Thalmann gave a rating of “Buy” to MBOT, setting the target price at $1.75 in the report published on January 31st of the previous year.
MBOT Trading at -12.70% from the 50-Day Moving Average
After a stumble in the market that brought MBOT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.68% of loss for the given period.
Volatility was left at 5.19%, however, over the last 30 days, the volatility rate increased by 5.98%, as shares sank -7.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.84% lower at present.
During the last 5 trading sessions, MBOT fell by -7.40%, which changed the moving average for the period of 200-days by -35.03% in comparison to the 20-day moving average, which settled at $0.9624. In addition, Microbot Medical Inc saw -46.52% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MBOT
Current profitability levels for the company are sitting at:
- -66.95 for the present operating margin
- 0.32 for the gross margin
The net margin for Microbot Medical Inc stands at -73.49. The total capital return value is set at -1.56. Equity return is now at value -134.46, with -113.94 for asset returns.
Based on Microbot Medical Inc (MBOT), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -53.06. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -144.05.
Currently, EBITDA for the company is -9.75 million with net debt to EBITDA at 0.25. When we switch over and look at the enterprise to sales, we see a ratio of 85.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.32.
Conclusion
In a nutshell, Microbot Medical Inc (MBOT) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
